News
-
-
-
COMMUNIQUÉ DE PRESSE
Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers
Valneva provides update on ACIP recommendation for its chikungunya vaccine IXCHIQ® among U.S. travelers, highlighting new precaution for persons aged 65 years and ongoing safety monitoring -
-
-
-
COMMUNIQUÉ DE PRESSE
Valneva et LimmaTech annoncent la vaccination du premier participant à l’étude pédiatrique de Phase 2 du candidat vaccin tétravalent contre la shigellose S4V2
Valneva et LimmaTech annoncent la vaccination du premier participant à l’étude pédiatrique de Phase 2 du candidat vaccin tétravalent contre la shigellose S4V2 -
COMMUNIQUÉ DE PRESSE
Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2
Valneva and LimmaTech announce first vaccination in Phase 2 infant study of tetravalent Shigella vaccine candidate S4V2. Study aims to combat shigellosis, a deadly diarrheal disease -
-
COMMUNIQUÉ DE PRESSE
Valneva Reports Full Year 2024 Results and Provides Business Updates and Outlook
Valneva SE reports solid full year 2024 results exceeding growth targets. Financial outlook for 2025 includes strong revenue growth and strategic investments. Key milestones and financial information discussed